Health and Human Services Secretary Alex Azar has described a new policy as “unleashing our Medicare Advantage plans to negotiate discounting on $12 billion of drugs.” Some patient advocacy groups have described the policy as one that “could erect barriers to care for cancer” and put “insurers in control of treatment decisions.” We’ll explain what the new policy entails.